Saccharomyces cerevisiae strain for reconstructing heme synthetic route in mitochondria and application

By reconstructing the heme synthesis pathway in the mitochondria of Saccharomyces cerevisiae, the problem of low heme synthesis efficiency in Saccharomyces cerevisiae is solved, efficient production of myoglobin and hemoglobin is achieved, and production costs are reduced.

CN120249085APending Publication Date: 2025-07-04JIANGNAN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202510305421.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-03-14
Publication Date
2025-07-04

AI Technical Summary

Technical Problem

The heme synthesis pathway in Saccharomyces cerevisiae has spatial isolation, resulting in low synthesis efficiency, insufficient ALA supply, unable to meet the needs of myoglobin and hemoglobin, and the cost of exogenous heme supplementation is high, making it difficult to be suitable for industrial production.

Method used

The heme synthesis pathway is reconstructed in the mitochondria of Saccharomyces cerevisiae, and the heme synthesis cytoplasmic enzyme is localized by localizing signal peptides. The mitochondrial ALA transporter gene ort1 is knocked out, and the mitochondrial heme transporter gene ygr127w is overexpressed, optimizing the heme synthesis pathway.

Benefits of technology

It improves the efficiency of heme synthesis, enhances the heme binding rate and activity of myoglobin and hemoglobin, reduces production costs, and is suitable for large-scale industrial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN120249085A_ABST
    Figure CN120249085A_ABST
Patent Text Reader

Abstract

The invention discloses a saccharomyces cerevisiae strain for reconstructing a heme synthetic route in mitochondria and application, and belongs to the technical field of gene engineering. According to the method, a heme synthesis route is reconstructed in the saccharomyces cerevisiae mitochondria, ALA and heme transporter in the mitochondria are excavated and modified, spatial isolation in the heme synthesis process is relieved, the capacity of intracellular self-synthesis of heme is enhanced, and synthesis of active heme protein is improved. According to the saccharomyces cerevisiae engineering strain constructed in the invention, the heme binding rates of porcine myoglobin and soybean hemoglobin are respectively increased by 2.4 times and 3.6 times, the specific activities of peroxidase are respectively increased by 56.4% and 73.6%, and the expression quantities of the two proteins are respectively increased by 31.1% and 42.1%; the improvement of the synthesis efficiency of the protein taking the heme as the prothetic group in the saccharomyces cerevisiae is facilitated.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a Saccharomyces cerevisiae strain for reconstructing a heme synthesis pathway in mitochondria and its application, belonging to the technical field of genetic engineering. Background Art

[0002] Myoglobin and hemoglobin are both important heme proteins, which play crucial roles in transporting and storing oxygen, binding and scavenging toxic nitric oxide, and regulating intracellular pH levels. In recent years, with the continuous in-depth research on these heme-binding proteins, they have been widely used as iron supplements, food additives, and colorants, showing great potential in the field of nutrition and health. Currently, leghemoglobin (LegH) has passed the FDA safety certification and is used as a food additive in cultured meat, giving cultured meat a real meat color and flavor. At the same time, porcine myoglobin (pMb) also plays an important role in improving meat color and texture. Saccharomyces cerevisiae, as a recognized food safety host, has been applied to the synthesis of various chemicals and has relatively complete gene editing tools, making it an ideal host for producing myoglobin and hemoglobin.

[0003] Heme is an important cofactor for the synthesis of myoglobin and hemoglobin. In Saccharomyces cerevisiae, the supply level of intracellular heme is very low, which cannot meet the actual demand for synthesizing heme-binding proteins. Moreover, the apolipoprotein without bound heme is very unstable and prone to degradation, which not only wastes cellular resources but also imposes a huge burden on cell growth. Although supplementing exogenous heme or 5-aminolevulinic acid (ALA) can promote protein synthesis and increase the heme-binding rate of proteins, it will increase costs and the effect of improving hemoglobin activity is limited, making it not suitable for large-scale industrial production. Therefore, it is necessary to strengthen the endogenous heme biosynthesis in the Saccharomyces cerevisiae host to express highly active myoglobin and hemoglobin.

[0004] There is a natural spatial barrier in the heme synthesis process of Saccharomyces cerevisiae. Heme is synthesized through eight enzyme-catalyzed steps in spatially separated mitochondria (Hem1p, Hem14p, and Hem15p) and cytoplasm (Hem2p, Hem3p, Hem4p, Hem12p, and Hem13p). This spatial isolation causes important intermediates in the heme synthesis pathway to cross the inner and outer mitochondrial membranes back and forth, reducing the synthesis and utilization efficiency of heme. Therefore, reconstructing the spatial distribution of the heme synthesis pathway is an effective means to improve the synthesis and utilization efficiency of heme.

[0005] Due to the lack of succinyl-CoA, the precursor for ALA synthesis, in the cytoplasm, the synthesis efficiency of ALA in the cytoplasm is low, and its normal supply in the heme synthesis pathway cannot be guaranteed. Therefore, reconstructing the heme synthesis pathway in mitochondria is a key issue for improving the production efficiency of myoglobin and hemoglobin in Saccharomyces cerevisiae. Summary of the Invention

[0006] The present invention first provides an engineered strain for reconstructing the heme synthesis pathway in mitochondria, which is based on the starting strain and has been improved by at least one of the following:

[0007] (1) Using the mitochondrial localization signal peptide MLS Cox4p To localize the heme synthesis cytoplasmic enzyme in mitochondria;

[0008] (2) Knocking out the mitochondrial ALA transporter gene ort1;

[0009] (3) Overexpressing the mitochondrial heme transporter gene ygr127w.

[0010] In one embodiment, the heme synthesis cytoplasmic enzyme includes one or more of Hem2p, Hem3p, Hem4p, Hem12p, and Hem13p.

[0011] In one embodiment, the mitochondrial localization signal peptide MLS Cox4p Is fused to the N-terminus of the heme synthesis cytoplasmic enzyme.

[0012] In one embodiment, the nucleotide sequence of the mitochondrial localization signal peptide MLS Cox4p Is as shown in SEQ ID NO.3.

[0013] In one embodiment, plasmid pY26 is used as the expression vector, and the promoter P TDH1 Regulates the expression of the heme synthase Hem2p fused with MLS Hem15p And the promoter P GPD Regulates the expression of the heme synthases Hem3p, Hem4p, Hem12p, and Hem13p fused with MLS Cox4p .

[0014] In one embodiment, the genes of the heme synthesis cytoplasmic enzymes fused with MLS are integrated at different sites in the genome.

[0015] In one embodiment, the starting strain integrates the coding gene of P TDH1 -MLS Hem15p -Hem2p-T CYC1 At the position of genomic 416d.

[0016] In one embodiment, based on the above engineering strain, the coding gene of P GPD -MLS Cox4p -Hem3p-T CYC1 is integrated at the position where genomic 308a is located.

[0017] In one embodiment, based on the above engineering strain, the coding gene of P GPD -MLS Cox4p -Hem4p-T CYC1 is integrated at the position where genomic 511b is located.

[0018] In one embodiment, based on the above engineering strain, the coding gene of P GPD -MLS Cox4p -Hem12p-T CYC1 is integrated at the position where genomic 1309a is located.

[0019] In one embodiment, based on the above engineering strain, the coding gene of P GPD -MLS Cox4p -Hem13p-T CYC1 is integrated at the position where genomic 720a is located.

[0020] In one embodiment, the nucleotide sequence of the mitochondrial heme transporter gene ygr127w is as shown in GeneID: 853028.

[0021] In one embodiment, the nucleotide sequence of the mitochondrial ALA transporter gene ort1 is as shown in Gene ID: 854297.

[0022] In one embodiment, the parental strains of the Saccharomyces cerevisiae include but are not limited to Saccharomyces cerevisiae and Saccharomyces uvarum.

[0023] In one embodiment, the engineered bacteria also express heme-binding proteins; the heme-binding proteins include but are not limited to functionally active porcine myoglobin (pMb) and leghemoglobin (LegH).

[0024] In one embodiment, the nucleotide sequence encoding porcine myoglobin (pMb) is as shown in SEQ ID NO.1; the nucleotide sequence encoding leghemoglobin (LegH) is as shown in SEQ ID NO.2.

[0025] In one embodiment, the porcine myoglobin and leghemoglobin use plasmid pESC as the expression vector.

[0026] The present invention also provides a method for increasing the metabolic flux of ALA in mitochondria. The method is based on the above engineering strain, knocking out the mitochondrial ALA transporter gene ort1 with the nucleotide sequence as shown in Gene ID: 854297, and / or overexpressing the mitochondrial heme transporter gene ygr127w with the nucleotide sequence as shown in Gene ID: 853028.

[0027] In one embodiment, the gene ygr127w uses plasmid pY26 as the expression vector and is regulated by the P GPD promoter for expression.

[0028] In one embodiment, the gene ygr127w is integrated into the lnt.1 locus of the engineering bacterium genome, and the nucleotide sequence of the lnt.1 locus is as shown in Genbank accession number: NC_001133.9 (175564..181563).

[0029] The present invention also provides a method for preparing myoglobin and / or hemoglobin, which is to ferment the above engineering bacterium in a fermentation medium at 28 - 30 °C for at least 48 h.

[0030] In one embodiment, the application is to ferment the genetically engineered bacterium in a fermentation medium at 30 °C and 220 rpm for at least 48 h.

[0031] In one embodiment, the fermentation medium includes but is not limited to YNB or YPD medium.

[0032] In one embodiment, when fermenting for 15 - 20 h, 10 - 50 g / L of galactose is added to the fermentation system for induction.

[0033] The present invention also provides the application of the above genetically engineered bacterium or the above method in the production of heme, myoglobin and / or hemoglobin products.

[0034] Beneficial effects:

[0035] (1) By using a suitable MLS and promoter, the present invention localizes five cytoplasmic enzymes (Hem2p, Hem3p, Hem4p, Hem12p and Hem13p) to mitochondria, eliminating the spatial isolation barrier in the heme synthesis process.

[0036] (2) One effective mitochondrial ALA transporter (Ort1p) was screened out from 8 mitochondrial transporters in the present invention. On the basis of the engineered strain with spatial isolation removed, by knocking out the ort1 gene and overexpressing the known mitochondrial heme transporter gene ygr127w, heme synthesis was enhanced, and the intracellular heme reached 0.43 ± 0.01 mg / L.

[0037] (3) Functional active porcine myoglobin and soybean hemoglobin were expressed in the engineered strain with enhanced heme synthesis ability constructed in the present invention, such that the heme binding rates of the above two heme-binding proteins were increased by 2.4 times and 3.6 times respectively, the POD specific activities were increased by 56.4% and 73.6% respectively, and the expressions of the above two proteins were also increased by 31.1% and 42.1% respectively, reaching 130.5 ± 2.8 mg / L and 152.8 ± 2.6 mg / L. BRIEF DESCRIPTION OF THE DRAWINGS

[0038] Figure 1 For the efficient mitochondrial localization of key enzymes for cytoplasmic heme synthesis. Among them, (A) is a schematic diagram for verifying the mitochondrial localization efficiency of five heme synthase by different combinations of MLS and promoters. (B) is MLS Cox4p Microscopic pictures and fluorescence scatter plots of the mitochondrial subcellular localization of Hem2p, Hem3p, Hem4p, Hem12p and Hem13p. (C) is MLS Cox4p Overlap coefficient values of two fluorescences for the mitochondrial localization of Hem2p, Hem3p, Hem4p, Hem12p and Hem13p. (D) is microscopic pictures and fluorescence scatter plots of the mitochondrial subcellular localization of Hem2p by different combinations of MLS and promoters. (E) is overlap coefficient values of two fluorescences for the mitochondrial localization of Hem2p by different combinations of MLS and promoters.

[0039] Figure 2 For the reconstruction of the heme synthesis pathway in the mitochondria of Saccharomyces cerevisiae. Among them, (A) is a schematic diagram of five heme synthases (Hem2p, Hem3p, Hem4p, Hem12p and Hem13p) in the cytoplasm being localized in the mitochondria through appropriate MLS. (B) is a schematic diagram for constructing recombinant strains HEME-1, HEME-2 and HEME-3. (The HEME-1 strain carries the integration cassette P TDH1 -MLS Hem15p -Hem2p-T CYC1 , P GPD -MLS Cox4p -Hem3p-T CYC1 , P GPD -MLS Cox4p -Hem4p-T CYC1, P GPD -MLS Cox4p -Hem12p-T CYC1 and P GPD -MLS Cox4p -Hem13p-T CYC1 ; The HEME-2 strain was obtained by knocking out the HEME2 gene on the basis of the HEME-1 strain; The HEME-3 strain carried the integration cassette P TDH1 -Hem2p-T CYC1 , P GPD -Hem3p-T CYC1 , P GPD -Hem4p-T CYC1 , P GPD -Hem12p-T CYC1 and P GPD -Hem13p-T CYC1 )(C) was for the verification of the integration and knockout strains. (D) was for the growth inhibition caused by the knockout of the HEM2 gene in the HEME-1 strain. (E) was for the biomass and intracellular heme production of the HEME-1 and HEME-3 strains at 24 h and 48 h.

[0040] Figure 3 was for the discovery and modification of ALA and heme transporters in the mitochondria of Saccharomyces cerevisiae. Among them, (A) was a schematic diagram of the separation of mitochondria and cytoplasm in Saccharomyces cerevisiae. (B) was a schematic diagram of the knockout of 8 mitochondrial amino acid transporters. (C) was the ALA content in mitochondria and cytoplasm in 8 knockout strains (CEN-Δagc1, CEN-Δhem25, CEN-Δmtm1, CEN-Δodc1, CEN-Δodc2, CEN-Δort1, CEN-Δymc1 and CEN-Δymc2). (D) was the effect of knocking out the ort1 gene (HEME-1-Δort1) in the HEME-1 strain on the ALA content in mitochondria and cytoplasm. (E) was the effect of overexpressing the ygr127w gene (HEME-1-Δort1-+ygr127w) in the HEME-1-Δort1 strain on the intracellular heme content.

[0041] Figure 4 was for the fermentation synthesis of high-efficiency myoglobin and hemoglobin at the shake flask level. Among them, (A) was the SDS-PAGE results of different engineered strains expressing pMb and LegH. (B) was the biomass and pMb and LegH expression levels of different engineered strains. (C) was the heme binding rate of pMb and LegH in different engineered strains. (D) was the peroxidase specific activity of pMb and LegH in different engineered strains. (E) was the characteristic absorption peaks of pMb and LegH in the HEME-1-Δort1-+ygr127w strain. Specific Embodiments

[0042] Hemin detection method: The intracellular hemin concentration was determined by the oxalic acid extraction method. Cells with OD 600 ×mL = 8 were placed in a brown centrifuge tube, and the cell pellet was centrifuged at 12,000 rpm for 5 min. The cell pellet was resuspended with deionized water and washed twice, and the supernatant was removed. Then, the cell pellet was mixed with 500 μL of 20 mM oxalic acid and placed at 4 °C for 16 h. After overnight incubation, the mixture was mixed with 500 μL of 2 M oxalic acid, and 500 μL of the mixture was incubated at 95 °C for 30 min, and the other half was placed at room temperature as a control. After incubation, the extract was centrifuged at 12,000 rpm for 5 min, and the supernatant was used for fluorescence measurement. Fluorescence was detected using a microplate reader (BioTek Synergy H1) at λ = 400 nm excitation and λ = 620 nm emission. Hemin (Aladdin) was used as a standard for calculating the hemin concentration.

[0043] Separation of mitochondria and cytoplasm: After the cells were incubated in DTT buffer, the yeast cells were washed with KClEM buffer (180 mM KCl, 1 mM EDTA, and 5 mM MOPS-KOH) (pH 7.2) and treated with yeast cell wall-lysing enzyme Zymolyase-20T, and then resuspended and washed in pre-cooled KClEM buffer. Subsequently, the centrifugation speed was increased successively (250×g, 2 min, 1000×g, 4 min, and 1900×g, 4 min) during centrifugation to precipitate the nucleus. The supernatant after the nucleus was centrifuged at 16,800×g for 15 min at high speed, and the precipitate was regarded as the mitochondrial fraction, and the supernatant was regarded as the cytoplasm.

[0044] ALA content detection method: 100 μL of acetylacetone and 200 μL of sodium acetate buffer (pH = 4.6) were added to 400 μL of the sample to be tested in sequence. The well-mixed solution was heated in boiling water for 15 min and then cooled to room temperature. Then, 700 μL of Ehrlich reagent (30 mL of glacial acetic acid, 1 g of DMAB, and 8 mL of 70% perchloric acid were added in sequence, dissolved with glacial acetic acid and diluted to a volume of 50 mL, and stored in the dark) was added. After reacting in the dark for 20 minutes, the absorbance was measured at 554 nm using a spectrophotometer (BioTek Synergy H1). A standard curve was plotted using ALA hydrochloride standard.

[0045] Methods for protein purification and quantification: Pick monoclonal colonies into 5 mL of SD-URA medium and culture at 30 °C and 220 rpm for 20 h. Inoculate 1% of the seed solution into a 250 mL shake flask containing 50 mL of YPD medium, then culture at 30 °C and 220 rpm for 18 h, add 2% galactose as an inducer, and continue fermentation for 48 h under the original conditions. After fermentation, centrifuge at 4 °C and 7000 rpm for 10 min to collect cells, and resuspend the cell pellet in 50 mL of pre-cooled PBS buffer (20 mM, pH 7.4), and then add a PMSF solution with a final concentration of 1 mM to prevent protein degradation. Use a high-pressure cell disruptor (UnionBiotech, Shanghai, China) to disrupt cells at 4 °C and 1000 bar, and collect the supernatant as a crude protein sample after centrifugation at 4 °C and 7000 rpm for 10 min. Use a PBS solution containing 50 mM imidazole as the washing buffer and a PBS solution containing 1 M imidazole as the elution buffer to purify the target protein through His Affinity (Ni NTA beads) agarose gel. Treat the purified protein in LDS sample buffer (Novex, Invitrogen) at 98 °C for 10 min, and then load the sample onto a sodium dodecyl sulfate-polyacrylamide gel electrophoresis (12%) for SDS-PAGE analysis of the protein purification effect. Bradford protein assay kit (Beyotime Biotech) is used to determine the concentration of the purified protein.

[0046] Method for detecting heme binding rate: Characterize the heme binding rate in proteins through the difference spectra between oxidized and reduced samples. Add 100 μL of the purified sample and 100 μL of Solution I (0.2 M NaOH, 40% (v / v) pyridine, 500 μM potassium ferricyanide) to a 96-well plate. After mixing evenly, scan the sample at intervals of 500 - 600 nm (wavelength interval is 1 nm) to obtain the oxidation spectrum. Add 2 μL of Solution II (0.5 M sodium dithionite dissolved in 0.5 M NaOH) to the oxidized sample. After mixing well again, the sample turns pink and is scanned at intervals of 500 - 600 nm to obtain the reduction spectrum. Use Beer's law to determine the heme binding rate, A = εc1 (absorbance = extinction coefficient × concentration × optical path length), and the ε of heme b 550-535 = 23.8 mM -1 cm -1 。

[0047] Methods for detecting protein biochemical properties:

[0048] (1) Determination of characteristic absorption peaks: 1 μM of purified myoglobin and hemoglobin were incubated in PBS buffer for 15 minutes. The samples were scanned at intervals of 300 - 700 nm using a microplate reader (BioTek Synergy H1) to obtain characteristic absorption peaks.

[0049] (2) ABTS (Solarbio, Shanghai, China) was used as a substrate to determine the peroxidase specific activity of purified myoglobin or hemoglobin.

[0050] Example 1 Efficient Mitochondrial Localization of Key Enzymes in Cytoplasmic Heme Synthesis

[0051] Using the genome of Saccharomyces cerevisiae CEN.PK2-1C as a template, the target genes HEM2 (nucleotide sequence as shown in Gene ID: 852842), HEM3 (nucleotide sequence as shown in Gene ID: 851322), HEM4 (nucleotide sequence as shown in Gene ID: 854452), HEM12 (nucleotide sequence as shown in Gene ID: 851617), and HEM13 (nucleotide sequence as shown in Gene ID: 851614) were amplified. The 5 , ends of the target genes were respectively ligated with the mitochondrial localization signal peptide MLS of cytochrome c oxidase subunit IV (COX4) Cox4p (nucleotide sequence as shown in SEQ ID NO.3), and the 3 , ends of the target genes were respectively ligated with the red fluorescent protein mScarlet (nucleotide sequence as shown in SEQ ID NO.4). Plasmids were constructed with pY26 as the backbone, and the expression of the genes was controlled by the constitutive promoter P GPD . Using the lithium acetate transformation method, they were respectively transformed into Saccharomyces cerevisiae CEN.PK2 1C to construct recombinant strains (MLS-HemXp-mScarlet). After verification by colony PCR and sequencing, correct positive clone strains were obtained. The cells were stained with Mito Tracker Green (MTG) to verify the mitochondrial localization effect of cytoplasmic heme synthase in Saccharomyces cerevisiae.

[0052] The results are as Figure 1 shown. The monochromatic fluorescence images were processed using ImageJ software. Among them, the recombinant strains MLS Cox4p -Hem2p-mScarlet, MLS Cox4p -Hem3p-mScarlet, MLS Cox4p -Hem4p-mScarlet, MLS Cox4p -Hem12p-mScarlet, and MLS Cox4pThe fluorescence overlap coefficients of the red fluorescent protein mScarlet and the green fluorescent dye MTG in -Hem13p-mScarlet reached 0.29±0.03, 0.93±0.01, 0.92±0.02, 0.92±0.01, and 0.89±0.01( Figure 1 ). This indicates that MLS Cox4p can efficiently localize cytoplasmic enzymes Hem3p, Hem4p, Hem12p, and Hem13p to mitochondria, but has a relatively poor effect on the mitochondrial localization of Hem2p. Among them, the nucleotide sequence of HEM2 is shown as Gene ID:852842; the nucleotide sequence of HEM3 is shown as Gene ID:851322; the nucleotide sequence of HEM4 is shown as Gene ID:854452; the nucleotide sequence of HEM12 is shown as Gene ID:851617; the nucleotide sequence of HEM13 is shown as Gene ID:851614; the nucleotide sequence of COX4 is shown as Gene ID:852688.

[0053] Using bioinformatics software TPPred 3.0, the MLS sequence (31 N-terminal residues) of mitochondrial heme synthase Hem15p was accurately predicted. The nucleotide sequence of HEM15 is shown as Gene ID:854347, and the nucleotide sequence of MLS Hem15p is shown as SEQ ID NO.5. Using the genomic DNA of Saccharomyces cerevisiae CEN.PK2-1C as a template, promoter fragments P TDH1 and P PGK1 were amplified, and plasmid pY26-P TDH1 -MLS Cox4p -Hem2p-mScarlet, pY26-P PGK1 -MLS Cox4p -Hem2p-mScarlet, pY26-P TDH1 -MLS Hem15p -Hem2p-mScarlet, and pY26-P PGK1 -MLS Hem15p -Hem2p-mScarlet were constructed using Gibson Assembly. The above four plasmids were respectively transformed into CEN.PK2-1C by the lithium acetate transformation method to construct four recombinant Saccharomyces cerevisiae strains. The cells were stained with MTG for mitochondria. The mitochondrial localization results of the new MLS and the strong constitutive promoter for Hem2p are shown as Figure 1 . Among them, the recombinant strain regulated by P TDH1 and localized by MLS Hem15p for Hem2p had a better mitochondrial localization effect, and the fluorescence overlap coefficient of the two fluorescences reached 0.87±0.04( Figure 1), higher than P GPD and MLS Hem15p and P PGK1 and MLS Hem15p combination.

[0054] Example 2 Reconstruction of the heme synthesis pathway in the mitochondria of Saccharomyces cerevisiae

[0055] Using the genome of Saccharomyces cerevisiae CEN.PK2-1C as a template, fragments of 500 bp each upstream and downstream of the cut416d gene sequence were amplified. Using the plasmid pY26-P TDH1 -MLS Hem15p -Hem2p-mScarlet constructed in Example 1 as a template, a target fragment containing the promoter P TDH1 , Hem2p with a highly efficient MLS, and the terminator T CYC1 was amplified to obtain the target fragment P TDH1 -MLS Cox4p -Hem2p-T CYC1 . Fusion PCR was used to ligate the upstream fragment, the target fragment, and the downstream fragment, a total of three fragments, to construct an integration cassette. The integration cassette was integrated at the 416d position of the Saccharomyces cerevisiae CEN.PK2-1C genome by CRISPR / Cas9 technology (the nucleotide sequence of this site is shown as Genbank accession number: NC_001136.10(463126..463145)), obtaining Saccharomyces cerevisiae CEN.PK2-1C cut416d::P TDH1 -MLS Hem15p -Hem2p-T CYC1 ; On this basis, at the 308a site of the Saccharomyces cerevisiae genome (the nucleotide sequence of this site is shown as Genbank accession number: NC_001135.5(114130..114149)), the 511b site (the nucleotide sequence of this site is shown as Genbank accession number: NC_001137.3(174990..175009)), the 1309a site (the nucleotide sequence of this site is shown as Genbank accession number: NC_001145.3(262867..262886)), and the 720a site (the nucleotide sequence of this site is shown as Genbank accession number: NC_001139.9(508439..508458)). According to the above method, the target fragment P TDH1 -MLS Hem15p -Hem2p-T CYC1 was successively integrated into the engineered strain CEN.PK2-1Ccut416d::P GPD -MLS Cox4p -Hem3p-T CYC1 , P GPD -MLSCox4p -Hem4p-T CYC1 ,P GPD -MLS Cox4p -Hem12p-T CYC1 and P GPD -MLS Cox4p -Hem13p-T CYC1 To obtain the recombinant strain HEME-1 that efficiently localizes five heme-synthesizing cytoplasmic enzymes to mitochondria.

[0056] Using the five plasmids containing highly efficient MLS and heme-synthesizing cytoplasmic enzymes constructed in Example 1 as templates, plasmids that do not carry MLS and only overexpress five heme-synthesizing cytoplasmic enzymes were constructed by Gibson Assembly. According to the above method, five integration cassettes containing heme-synthesizing cytoplasmic enzymes were integrated at five different sites in the genome of Saccharomyces cerevisiae CEN.PK2-1C through the CRISPR / Cas9 technology to obtain the recombinant strain HEME-2 that only overexpresses five heme-synthesizing cytoplasmic enzymes and does not carry MLS. In YPD medium, inoculate bacterial cells at a final concentration of 1×10 7 ~1×10 8 CFU / mL, and ferment at 30 °C and 220 rpm for 48 h. During fermentation, the intracellular heme content of the recombinant strains HEME-1 and HEME-3 was detected by the method of oxalic acid extraction (refer to the paper "Sequential induction of heme pathway enzymes during erythroid differentiation of mouse Friend leukemia virus-infected cells; Identification and treatment of heme depletion attributed to overexpression of a lineage of evolved P450 monooxygenases."). Saccharomyces cerevisiae CEN.PK2-1C was used as a control strain to determine the effect of the reconstruction of the heme synthesis pathway in mitochondria on the intracellular heme content. The results are as Figure 2 shown. After 24 h of fermentation, the intracellular heme contents of HEME-1 and HEME-3 were 7.6 times and 2.8 times that of the control group, reaching 0.40 ± 0.04 mg / L and 0.15 ± 0.02 mg / L ( Figure 2 ). Therefore, the reconstruction of the heme synthesis pathway in mitochondria significantly increases the intracellular heme content, which is much higher than the effect of only overexpressing the key enzymes of the heme synthesis pathway on the intracellular heme content.

[0057] Knock out the key gene hem2 in the heme biosynthesis pathway of the Saccharomyces cerevisiae HEME-1 strain by CRISPR-Cas9 technology. Use fusion PCR to ligate two fragments, the 700 bp upstream homologous arm and the 700 bp downstream homologous arm of the target gene, to construct a knockout cassette. Use the lithium acetate transformation method to screen positive clone strains on SD-URA plates, and use 5-FOA to eliminate the URA tag to obtain the HEME-1-Δhem2 strain. Inoculate the HEME-2 strain, the control strain CEN.PK2-1C, and the HEME-1 strain into 50 / 250 mL shake flasks respectively, and detect the biomass of different strains by OD 600 After culturing the cells for 36 h, the biomass of the HEME-2 strain (OD 600 = 7.01 ± 0.11) decreased by 55.1% compared with the HEME-1 strain (OD 600 = 15.61 ± 0.38), and decreased by 57.6% compared with the wild-type strain CEN.PK2-1 (OD 600 = 16.52 ± 0.41) ( Figure 2 ). Therefore, the original cytoplasmic pathway in heme synthesis should be retained to meet the normal growth of the strain.

[0058] Example 3 Mining and modification of ALA and heme transporters in the mitochondria of Saccharomyces cerevisiae

[0059] Use CRISPR-Cas9 technology to knock out the mitochondrial transporter genes agc1, hem25, mtm1, odc1, odc2, ort1, ymc1, and ymc2 related to amino acid transport in the Saccharomyces cerevisiae CEN.PK2-1 strain respectively, and obtain the recombinant strains CEN-Δagc1, CEN-Δhem25, CEN-Δmtm1, CEN-Δodc1, CEN-Δodc2, CEN-Δort1, CEN-Δymc1, and CEN-Δymc2 respectively. Among them, the nucleotide sequence of agc1 is shown as Gene ID: 856132; the nucleotide sequence of hem25 is shown as Gene ID: 851439; the nucleotide sequence of mtm1 is shown as Gene ID: 853173; the nucleotide sequence of odc1 is shown as Gene ID: 855969; the nucleotide sequence of odc2 is shown as Gene ID: 854397; the nucleotide sequence of ort1 is shown as GeneID: 854297; the nucleotide sequence of ymc1 is shown as Gene ID: 856171; the nucleotide sequence of ymc2 is shown as GeneID: 852401.

[0060] To determine whether these eight mitochondrial transporter genes can play a role in ALA transport, Saccharomyces cerevisiae CEN.PK2-1C was used as a control strain. The control strain and the recombinant strains CEN-Δagc1, CEN-Δhem25, CEN-Δmtm1, CEN-Δodc1, CEN-Δodc2, CEN-Δort1, CEN-Δymc1, and CEN-Δymc2 were respectively cultured in SC medium supplemented with 20 mg / L ALA and 2% galactose at 30 °C and 130 rpm for 24 h. Mitochondria and cytoplasm were separated. After ultrasonic lysis of the mitochondria, the ALA content in the mitochondria and cytoplasm of different strains was measured by a colorimetric method. The results showed that the ALA accumulation in the mitochondria of the CEN-Δort1 strain reached 1.19 ± 0.17 mg / L, which was 3.4 times that of the control strain (0.35 ± 0.08 mg / L). The ALA content in the cytoplasm of the CEN-Δort1 strain was 4.61 ± 0.06 mg / L, which decreased by 14.2% compared with the control strain (5.37 ± 0.15 mg / L) ( Figure 3 ). Therefore, the mitochondrial transporter Ort1p of Saccharomyces cerevisiae was identified as an ALA transporter.

[0061] The ALA transporter gene ort1 in the HEME-1 strain constructed in Example 2 was knocked out by the CRISPR-Cas9 technique to obtain the recombinant strain HEME-1-Δort1. Compared with the CEN-Δort1 strain, the mitochondrial ALA content of the HEME-1-Δort1 strain (0.94 ± 0.12 mg / L) decreased by 10.9%; compared with the CEN.PK2-1C strain, the intracellular heme content of the HEME-1-Δort1 strain increased by 6.6% ( Figure 3 ).

[0062] The above results indicate that the reconstituted heme synthesis pathway functions in mitochondria, and ALA is effectively used for heme synthesis. On this basis, the heme transporter gene ygr127w was continuously overexpressed in the HEME-1-Δort1 strain by the CRISPR-Cas9 technique. The specific steps were as follows: Referring to the method of Example 1, plasmid pY26-P GPD- ygr127w was constructed, and the expression cassette P GPD -Ygr127w-T CYC1Integrated at the lnt.1 locus of the engineered strain HEME-1-Δort1- genome (the nucleotide sequence of this locus is shown as Genbank accession number: NC_001133.9 (175564..181563)). The recombinant strain HEME-1-Δort1-+ygr127w was obtained and fermented at 30 °C and 220 rpm for 48 h. During fermentation, the intracellular heme content of the HEME-1-Δort1-+ygr127w strain was detected by the method of oxalic acid extraction. The intracellular heme content of the HEME-1-Δort1-+ygr127w strain reached 0.43 ± 0.01 mg / L, which was 9.1% higher than that of the HEME-1 strain and 8.4 times that of the CEN.PK2-1C strain ( Figure 3 ). Therefore, the HEME-1-Δort1-+ygr127w strain can be used as the best heme supply strain for synthesizing highly active heme-binding proteins. The nucleotide sequence of ygr127w is shown as Gene ID: 853028.

[0063] Example 4 Fermentation at shake flask level for synthesizing highly efficient myoglobin and hemoglobin

[0064] Plasmids pESC-pMb carrying porcine myoglobin (the nucleotide sequence encoding porcine myoglobin pMb is shown as SEQ ID NO.1, and this plasmid is disclosed in the paper "Systematic engineering of Saccharomyces cerevisiae for efficient synthesis of hemoglobins and myoglobins") or plasmid pESC-LegH carrying the soybean hemoglobin-encoding gene (i.e., pESC-sMb, disclosed in the paper "Systematic engineering of Saccharomyces cerevisiae for efficient synthesis of hemoglobins and myoglobins", and the nucleotide sequence encoding soybean hemoglobin LegH is shown as SEQ ID NO.2) were respectively introduced into the cells of the control strain CEN.PK2-1C, the recombinant strain HEME-1 constructed in Example 2, and the recombinant strains HEME-1-Δort1 and HEME-1-Δort1-+ygr127w constructed in Example 3, to obtain the recombinant strains CEN-pMb, HEME-1-pMb, HEME-1-Δort1-pMb, HEME-1-Δort1-+ygr127w-pMb, CEN-LegH, HEME-1-LegH, HEME-1-Δort1-LegH, and HEME-1-Δort1-+ygr127w-LegH with the ability to synthesize porcine myoglobin and soybean hemoglobin. The above recombinant strains were respectively inoculated into the YPD fermentation medium to make the cell concentration after inoculation be 1×10 7 ~1×10 8 CFU / mL, and fermented at 30 °C and 220 rpm for 48 h. The intracellular protein expression level, heme binding rate, and protein biochemical properties were detected. The results showed that compared with the control strain CEN.PK2-1C, the yields of porcine myoglobin and soybean hemoglobin of the engineered strain HEME-1-Δort1-+ygr127w were increased by 31.1% and 42.1% respectively, reaching 130.5 ± 2.8 mg / L and 152.8 ± 2.6 mg / L; the heme binding rates of porcine myoglobin and soybean hemoglobin were increased by 2.4 times and 3.6 times respectively, reaching 52.4 ± 4.9% and 75.5 ± 2.8%; the POD specific activities of porcine myoglobin and soybean hemoglobin were increased by 56.4% and 73.6% respectively, reaching 168.7 ± 6.6 U / mg and 192.7 ± 2.9 U / mg( Figure 4 ).

[0065] Although the present invention has been disclosed above in preferred embodiments, it is not intended to limit the present invention. Anyone skilled in this technology can make various modifications and alterations without departing from the spirit and scope of the present invention. Therefore, the protection scope of the present invention should be defined by the claims.

Claims

1. An engineered bacterium producing heme, characterized in that, On the basis of the starting strain, at least one of the following improvements was made: (1) Use the mitochondrial localization signal peptide MLS Cox4p Localize the heme-synthesizing cytoplasmic enzyme in the mitochondria; the heme-synthesizing cytoplasmic enzyme includes one or more of Hem2p, Hem3p, Hem4p, Hem12p, and Hem13p; (2) Knock out the mitochondrial ALA transporter gene ort1; (3) Overexpress the mitochondrial heme transporter gene ygr127w.

2. The engineered bacterium according to claim 1, characterized in that, The mitochondrial localization signal peptide MLS Cox4p is fused to the N-terminus of the heme synthesis cytoplasmic enzyme.

3. The engineered bacterium according to claim 1 or 2, characterized in that, Using promoter P TDH1 to regulate the expression of the fused MLS Hem15p of heme synthase Hem2p, and using promoter P GPD to regulate the expression of the fused MLS Cox4p of heme synthases Hem3p, Hem4p, Hem12p, and Hem13p.

4. The engineered bacteria according to any one of claims 1 to 3, characterized in that, The gene ygr127w is integrally expressed on the genome of the engineered bacterium.

5. The engineered bacteria according to any one of claims 1 to 4, characterized in that, The starting strain includes but is not limited to Saccharomyces cerevisiae or Saccharomyces uvarum.

6. The engineered bacterium according to any one of claims 1 to 5, characterized in that, It also expresses a heme-binding protein; the heme-binding protein includes but is not limited to porcine myoglobin and soybean hemoglobin.

7. The engineered bacterium according to claim 6, wherein Using plasmid pESC as an expression vector, porcine myoglobin or soybean hemoglobin is expressed.

8. A method for increasing the metabolic flux of ALA in mitochondria, characterized in that, At least one of the following improvements was made to the starting strain: (1) Use the mitochondrial localization signal peptide MLS Cox4p Localize the heme synthesis cytoplasmic enzyme in the mitochondrion; the heme synthesis cytoplasmic enzyme includes one or more of Hem2p, Hem3p, Hem4p, Hem12p, and Hem13p; (2) Knock out the mitochondrial ALA transporter gene ort1; (3) Overexpress the mitochondrial heme transporter gene ygr127w.

9. A method for preparing myoglobin and / or hemoglobin, characterized in that, The engineered bacterium described in claim 6 or 7 is fermented in a fermentation medium at 28-30 °C for at least 48 h.

10. Use of the engineered bacterium according to any one of claims 1-7 or the method according to any one of claims 8-9 in the production of heme, myoglobin and / or hemoglobin products.